A test by the Australian Racing Forensic Laboratory (ARFL) of samples from a newly prepared batch of Bova’s 100mg/ml injectable omeprazole formulation did not detect testosterone, and Racing New South Wales has now released a statement that the product can continue to be used in racehorses following the guidance of Australian Commonwealth and State legislation.
Nick Bova, managing director of Bova UK, said: "Traces of testosterone in the previous batch were less than one millionth of the internationally accepted standard for impurities.
"Independent experts confirmed that there could be no adverse effects on equine health or equestrian sport, however, we have taken steps to identify and completely eliminate the excipient ingredient that contained traces of testosterone."
Nick added: "Bova can confirm that new batches of this product will not contain the previous trace levels of testosterone and therefore Bova are confident there will be no antidoping issues, no matter what the equestrian pursuit is."
The Australian company, which launched in the UK offering equine specials in March 2017, says that while some human healthcare companies are authorised to supply veterinary specials under licence in the UK, it is currently the only company in the UK to have specific veterinary authorisation to manufacture sterile specials.
There are six formulations in Bova’s new small animal range with a further 23 formulations scheduled to be introduced in the first half of 2018. However, Bova says that due to advertising restrictions, only verified veterinary surgeons will be able to see its formulation list.
For more information, contact Bova Sales Manager Emma Jones on tel: 07780443731 or Victoria Dawson on 07780443738 or visit www.bova.co.uk.
The company will also be at BSAVA Congress this week on stand 817, where they will be offering the chance to win an afternoon champagne tea at the Ritz.